■高泌乳素血症与肥胖有关,血脂异常,胰岛素抵抗,和可能促进内皮功能障碍(EnD)的低度炎症。在泌乳素瘤的EnD方面做了有限的工作,我们,因此,研究了多巴胺激动剂治疗前后泌乳素瘤患者炎症和EnD的血清标志物。
■56名未经治疗的泌乳素腺瘤患者和53名(年龄和性别明显健康)对照者被纳入研究,并接受临床评估和实验室检查,包括血糖,总胆固醇,甘油三酯,低密度脂蛋白胆固醇,高密度脂蛋白胆固醇,尿素,肌酐,尿酸,红细胞沉降率(ESR),高敏C反应蛋白(hsCRP)和EnD标志物,即细胞间粘附分子-1(ICAM-1)和血管细胞粘附分子-1(VCAM-1)。患者接受多巴胺激动剂(卡麦角林)和参数(如ESR,hsCRP,在12周时测量ICAM-1和VCAM-1)。
■大多数患者(84%)是女性,超过一半(52%)患有代谢综合征,超过三分之一(36%)患有肥胖.空腹血糖,HbA1c,脂质部分,ESR,hsCRP,患者的ICAM-1和VCAM-1明显高于对照组。患者的ICAM-1中位数为1331.95ng/ml(IQR803.43-1825.99),对照组为753.04ng/ml(IQR402.04-871.55),P<0.001,患者的VCAM-1中位数为971.35ng/ml(IQR695.03-1285.23),而对照组为634.56ng/ml(IQR177.49-946.50),p0.001。血清ICAM-1和VCAM-1与hsCRP呈正相关。在多元回归分析中,血清hsCRP是ICAM-1和VCAM-1变化的唯一显著预测因子。血清PRL与CAB的标准化导致代谢参数的显着降低,ESR,hsCRP,ICAM-1和VCAM-1。
■由于催乳素瘤引起的高催乳素血症与继发于全身性炎症和代谢异常的EnD相关,后者在DA治疗后改善。
UNASSIGNED: Hyperprolactinemia is associated with obesity, dyslipidemia, insulin resistance, and low-grade inflammation which may promote endothelial dysfunction (EnD). Limited work has been done on EnD in prolactinomas and we, therefore, studied serum markers of inflammation and EnD in patients with prolactinomas before and after treatment with dopamine agonists.
UNASSIGNED: Fifty-six treatment naïve patients with prolactinomas and fifty-three (apparently healthy age and sex-matched) controls were enrolled in the study and subjected to clinical assessment and laboratory investigations including blood glucose, total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, urea, creatinine, uric acid, erythrocyte sedimentation rate (ESR), highly sensitive C-reactive protein (hsCRP) and markers of EnD i.e., intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Patients were treated with a dopamine agonist (cabergoline) and parameters (like ESR, hsCRP, ICAM-1, and VCAM-1) were measured at 12 weeks.
UNASSIGNED: The majority of the patients (84%) were female, more than half (52%) had metabolic syndrome and over a third (36%) were obese. Blood glucose fasting, HbA1c, lipid fractions, ESR, hsCRP, ICAM-1, and VCAM-1 were significantly higher in patients than in controls. Median ICAM-1 was 1331.95 ng/ml (IQR 803.43-1825.99) in patients vs 753.04 ng/ml (IQR 402.04-871.55) in controls, P < 0.001 and median VCAM-1in patients was 971.35 ng/ml (IQR 695.03-1285.23) as against 634.56 ng/ml (IQR 177.49-946.50) in controls, p0.001. Serum ICAM-1 and VCAM-1 correlated positively with hsCRP. On multivariate regression analysis, serum hsCRP was the only significant predictor of change in ICAM-1 and VCAM-1. Normalization of serum PRL with CAB resulted in a significant decrease in metabolic parameters, ESR, hsCRP, ICAM-1, and VCAM-1.
UNASSIGNED: Hyperprolactinemia because of prolactinoma is associated with EnD secondary to systemic inflammation and metabolic abnormalities which improve after treatment with DA.